HK1247125A1 - 结晶化合物 - Google Patents

结晶化合物 Download PDF

Info

Publication number: HK1247125A1
Authority: HK; Hong Kong
Prior art keywords: crystalline compounds; same; naphthalen; azabicyclo; compositions
Prior art date: 2015-06-17

Application number

HK18106861.3A

Other languages

English (en)

Inventor

Anthony Alexander Mckinney

Franklin Bymaster

Walter Piskorski

Fred J. Fleitz

Yonglai Yang

David A. Engers

Valeriya Smolenskaya

Venkat Kusukuntla

Original Assignee

Otsuka America Pharmaceutical, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-06-17

Filing date

2016-06-17

Publication date

2018-09-21

2016-06-17 Application filed by Otsuka America Pharmaceutical, Inc. filed Critical Otsuka America Pharmaceutical, Inc.

2018-09-21 Publication of HK1247125A1 publication Critical patent/HK1247125A1/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C211/00—Compounds containing amino groups bound to a carbon skeleton
- C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
- C07C211/16—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings
- C07C211/17—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings other than six-membered aromatic rings containing only non-condensed rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Neurology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Psychiatry (AREA)
Addiction (AREA)
Epidemiology (AREA)
Pain & Pain Management (AREA)
Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Indole Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Crystals, And After-Treatments Of Crystals (AREA)

HK18106861.3A 2015-06-17 2016-06-17 结晶化合物 HK1247125A1 (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201562181174P	2015-06-17	2015-06-17
US62/181,174		2015-06-17
PCT/US2016/038256 WO2016205762A1 (en)	2015-06-17	2016-06-17	Crystalline compounds

Publications (1)

Publication Number	Publication Date
HK1247125A1 true HK1247125A1 (zh)	2018-09-21

Family

ID=57546597

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK18106861.3A HK1247125A1 (zh)	2015-06-17	2016-06-17	结晶化合物

Country Status (25)

Country	Link
US (5)	US9708261B2 (zh)
EP (3)	EP3597189B1 (zh)
JP (4)	JP6896651B2 (zh)
KR (1)	KR102593783B1 (zh)
CN (3)	CN117466800A (zh)
AU (2)	AU2016279075C1 (zh)
CA (2)	CA3200692A1 (zh)
CY (1)	CY1125352T1 (zh)
DK (1)	DK3597189T3 (zh)
ES (1)	ES2922158T3 (zh)
HK (1)	HK1247125A1 (zh)
HR (1)	HRP20220829T1 (zh)
HU (1)	HUE059348T2 (zh)
LT (1)	LT3597189T (zh)
MX (2)	MX387591B (zh)
MY (1)	MY194868A (zh)
NZ (2)	NZ776973A (zh)
PH (1)	PH12017502324A1 (zh)
PL (1)	PL3597189T3 (zh)
PT (1)	PT3597189T (zh)
SA (1)	SA517390552B1 (zh)
SG (1)	SG10201911417PA (zh)
SI (1)	SI3597189T1 (zh)
TW (1)	TWI751998B (zh)
WO (1)	WO2016205762A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP5184354B2 (ja)	2005-07-27	2013-04-17	ユーシミクスバイオサイエンス，インク．	新規１−アリール−３−アザビシクロ［３．１．０］ヘキサン：調製および神経精神障害の処理への使用
US20140206740A1 (en)	2011-07-30	2014-07-24	Neurovance, Inc.	Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20160303077A1 (en)	2013-12-09	2016-10-20	Neurovance, Inc.	Novel compositions
DK3597189T3 (da)	2015-06-17	2022-06-27	Otsuka America Pharmaceutical Inc	Krystallinske forbindelser
US11149004B2 (en) *	2017-12-11	2021-10-19	Crystal Pharmaceutical (Suzhou) Co., Ltd.	Crystalline form of EB-1020, processes for preparation and use thereof
WO2021075494A1 (ja) *	2019-10-16	2021-04-22	大塚製薬株式会社	センタナファジンの製造方法
US20240246914A1 (en)	2021-05-31	2024-07-25	Teva Pharmaceuticals International Gmbh	Solid state form of centanafadine hcl and process for preparation thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1562900A4 (en)	2002-11-08	2006-07-12	Dov Pharmaceutical Inc	POLYMORPH OF BICIFADINHYDROCHLORIDE
EA010198B1 (ru)	2004-04-19	2008-06-30	Крка, Товарна Здравил, Д.Д., Ново Место	Способы получения полиморфной формы i гидросульфата клопидогрела
CN101052393A (zh)	2004-08-18	2007-10-10	Dov药物公司	氮杂双环己烷的新型多晶型物
US20070043100A1 (en)	2005-08-16	2007-02-22	Hagen Eric J	Novel polymorphs of azabicyclohexane
US20070082939A1 (en)	2005-07-26	2007-04-12	Lippa Arnold S	Methods and compositions for the treatment of neuropathies and related disorders
JP5184354B2 (ja)	2005-07-27	2013-04-17	ユーシミクスバイオサイエンス，インク．	新規１−アリール−３−アザビシクロ［３．１．０］ヘキサン：調製および神経精神障害の処理への使用
US7919598B2 (en)	2006-06-28	2011-04-05	Bristol-Myers Squibb Company	Crystal structures of SGLT2 inhibitors and processes for preparing same
US20080058535A1 (en) *	2006-07-25	2008-03-06	Zhengming Chen	Methods and compositions for production, formulation and use of 1 aryl-3-azabicyclo[3.1.0]hexanes
US8576985B2 (en)	2009-09-01	2013-11-05	Aptuit (West Lafayette) Llc	Methods for indexing solid forms of compounds
KR20130105675A (ko) *	2010-11-25	2013-09-25	라티오팜 게엠베하	아파티닙의 신규 염 및 다형
EP2819516B1 (en)	2011-07-30	2019-12-25	Otsuka America Pharmaceutical, Inc.	Use of (1r,5s)-(+)-1-(naphthalen-2-yl)-3-azabicyclo{3.1.0}hexane in the treatment of conditions affected by monoamine neurotransmitters
US20140206740A1 (en)	2011-07-30	2014-07-24	Neurovance, Inc.	Use Of (1R,5S)-(+)-(Napthalen-2-yl)-3-Azabicyclo[3.1.0]Hexane In The Treatment Of Conditions Affected By Monoamine Neurotransmitters
US20140228421A1 (en)	2011-09-07	2014-08-14	Anthony McKinney	Methods For Inhibiting Native And Promiscuous Uptake Of Monoamine Neurotransmitters
US20160303077A1 (en)	2013-12-09	2016-10-20	Neurovance, Inc.	Novel compositions
DK3597189T3 (da)	2015-06-17	2022-06-27	Otsuka America Pharmaceutical Inc	Krystallinske forbindelser

2016
- 2016-06-17 DK DK19196556.5T patent/DK3597189T3/da active
- 2016-06-17 WO PCT/US2016/038256 patent/WO2016205762A1/en not_active Application Discontinuation
- 2016-06-17 US US15/186,415 patent/US9708261B2/en active Active
- 2016-06-17 PL PL19196556.5T patent/PL3597189T3/pl unknown
- 2016-06-17 LT LTEP19196556.5T patent/LT3597189T/lt unknown
- 2016-06-17 KR KR1020187001083A patent/KR102593783B1/ko active Active
- 2016-06-17 EP EP19196556.5A patent/EP3597189B1/en active Active
- 2016-06-17 CN CN202310843667.7A patent/CN117466800A/zh active Pending
- 2016-06-17 CA CA3200692A patent/CA3200692A1/en active Pending
- 2016-06-17 NZ NZ776973A patent/NZ776973A/en unknown
- 2016-06-17 SI SI201631552T patent/SI3597189T1/sl unknown
- 2016-06-17 HK HK18106861.3A patent/HK1247125A1/zh unknown
- 2016-06-17 HU HUE19196556A patent/HUE059348T2/hu unknown
- 2016-06-17 AU AU2016279075A patent/AU2016279075C1/en active Active
- 2016-06-17 CN CN201680035027.1A patent/CN107921021A/zh active Pending
- 2016-06-17 CA CA2989431A patent/CA2989431C/en active Active
- 2016-06-17 MX MX2017016430A patent/MX387591B/es unknown
- 2016-06-17 HR HRP20220829TT patent/HRP20220829T1/hr unknown
- 2016-06-17 ES ES19196556T patent/ES2922158T3/es active Active
- 2016-06-17 PT PT191965565T patent/PT3597189T/pt unknown
- 2016-06-17 SG SG10201911417PA patent/SG10201911417PA/en unknown
- 2016-06-17 NZ NZ739044A patent/NZ739044A/en unknown
- 2016-06-17 EP EP22164478.4A patent/EP4049997A1/en active Pending
- 2016-06-17 MY MYPI2017704811A patent/MY194868A/en unknown
- 2016-06-17 JP JP2017565236A patent/JP6896651B2/ja active Active
- 2016-06-17 CN CN202310848120.6A patent/CN117088802A/zh active Pending
- 2016-06-17 EP EP16812592.0A patent/EP3310352A4/en not_active Ceased
- 2016-12-21 TW TW105142467A patent/TWI751998B/zh active
2017
- 2017-06-01 US US15/611,580 patent/US9856217B2/en active Active
- 2017-11-21 US US15/820,241 patent/US10280141B2/en active Active
- 2017-12-14 SA SA517390552A patent/SA517390552B1/ar unknown
- 2017-12-15 PH PH12017502324A patent/PH12017502324A1/en unknown
- 2017-12-15 MX MX2020009949A patent/MX2020009949A/es unknown
2019
- 2019-03-11 US US16/298,179 patent/US10800740B2/en active Active
2020
- 2020-08-14 US US16/993,648 patent/US11299458B2/en active Active
2021
- 2021-01-19 AU AU2021200314A patent/AU2021200314B2/en active Active
- 2021-06-09 JP JP2021096354A patent/JP7244575B2/ja active Active
2022
- 2022-07-11 CY CY20221100470T patent/CY1125352T1/el unknown
2023
- 2023-03-09 JP JP2023036730A patent/JP7583851B2/ja active Active
2024
- 2024-11-01 JP JP2024192608A patent/JP2025022896A/ja active Pending

Also Published As

Publication number	Publication date
EP3597189A1 (en)	2020-01-22
US20180194726A1 (en)	2018-07-12
AU2016279075C1 (en)	2021-04-01
KR20180014830A (ko)	2018-02-09
HUE059348T2 (hu)	2022-11-28
MX2020009949A (es)	2020-10-16
CA3200692A1 (en)	2016-12-22
US10800740B2 (en)	2020-10-13
US9856217B2 (en)	2018-01-02
NZ776973A (en)	2022-11-25
MX2017016430A (es)	2018-11-09
CA2989431C (en)	2023-08-29
PT3597189T (pt)	2022-07-05
US20210198198A1 (en)	2021-07-01
TW201800392A (zh)	2018-01-01
US20200039934A1 (en)	2020-02-06
CY1125352T1 (el)	2025-05-09
US9708261B2 (en)	2017-07-18
AU2016279075A1 (en)	2018-02-01
TWI751998B (zh)	2022-01-11
RU2018101244A3 (zh)	2019-12-23
JP2025022896A (ja)	2025-02-14
AU2021200314A1 (en)	2021-03-18
AU2016279075B2 (en)	2020-10-22
CN117466800A (zh)	2024-01-30
SA517390552B1 (ar)	2022-04-13
JP6896651B2 (ja)	2021-06-30
SI3597189T1 (sl)	2022-08-31
EP3597189B1 (en)	2022-06-01
JP7583851B2 (ja)	2024-11-14
JP2021138747A (ja)	2021-09-16
CA2989431A1 (en)	2016-12-22
KR102593783B1 (ko)	2023-10-25
CN117088802A (zh)	2023-11-21
NZ739044A (en)	2022-08-26
WO2016205762A1 (en)	2016-12-22
ES2922158T3 (es)	2022-09-09
JP2023071978A (ja)	2023-05-23
US20160368871A1 (en)	2016-12-22
US11299458B2 (en)	2022-04-12
HRP20220829T1 (hr)	2022-12-23
EP3310352A4 (en)	2019-03-13
CN107921021A (zh)	2018-04-17
MY194868A (en)	2022-12-21
PH12017502324A1 (en)	2018-06-25
SG10201911417PA (en)	2020-01-30
PL3597189T3 (pl)	2022-07-25
MX387591B (es)	2025-03-18
EP4049997A1 (en)	2022-08-31
LT3597189T (lt)	2022-07-11
AU2021200314B2 (en)	2022-08-04
US20170334850A1 (en)	2017-11-23
JP7244575B2 (ja)	2023-03-22
JP2018517742A (ja)	2018-07-05
DK3597189T3 (da)	2022-06-27
US10280141B2 (en)	2019-05-07
EP3310352A1 (en)	2018-04-25
RU2018101244A (ru)	2019-07-22

Publication	Publication Date	Title
HK1247125A1 (zh)	2018-09-21	结晶化合物
IL260330B (en)	2021-07-29	Ketohexokinase inhibitors
EP3665156A4 (en)	2021-04-28	COMPOUNDS, COMPOSITIONS, AND PROCEDURES
IL282460A (en)	2021-06-30	The compound 2-azabicyclohexane as a JAK inhibitor
EP3675859A4 (en)	2021-06-30	COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
WO2016011306A3 (en)	2016-03-10	Terminal modifications of polynucleotides
HK1216859A1 (zh)	2016-12-09	Irak抑制劑和其用途
EP3233809A4 (en)	2018-05-30	Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide
EP3279207A4 (en)	2018-11-14	Novel compound of 4'-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
EP3250557A4 (en)	2018-06-20	Isotopologues of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide
WO2015197534A3 (en)	2016-03-17	Methods for the preparation of 1,3-benzodioxole heterocyclic compounds
PH12016501472B1 (en)	2019-05-31	Solid forms of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide, compositions thereof and methods of their use
WO2016013030A3 (en)	2016-03-31	Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
WO2016092561A3 (en)	2016-10-06	Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
WO2015095659A3 (en)	2015-10-15	Indirubin solid dispersion composition
MX2016013439A (es)	2016-11-17	Formas solidas de un compuesto farmaceuticamente activo.
IL262850A (en)	2018-12-31	Derived from prostaglandin, preparations containing it and uses
WO2014159501A3 (en)	2014-11-20	Processes for preparing tetrahydroisoquinolines
EP3576769A4 (en)	2021-01-13	COMPOUNDS, COMPOSITIONS, AND USES THEREOF FOR IMPROVEMENT OF BONE DISEASES
WO2012139074A3 (en)	2012-12-13	Migrastatins and uses thereof
WO2017046816A3 (en)	2017-04-27	Process for the preparation of derivatives of benzodioxole
WO2015104602A3 (en)	2015-12-10	A process for the preparation of anagliptin and its intermediates thereof
HK40054653A (zh)	2022-02-25	2-氮杂环己烷化合物作为jak抑制剂
WO2016085160A3 (ko)	2016-12-01	발모촉진용 또는 탈모방지용 조성물
HK1220194A1 (zh)	2017-04-28	去氮雜去鐵硫代黴素(desazadesferrithiocin)類似物的多晶型形式